Hepatobiliary Imaging

Updated: August 22, 2023

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

technetium tc-99m mebrofenin

For the Patient Body weight of 70 kg
The recommended dosage is 2-5 mCi, equivalent to (74-185 MBq) administered intravenously

technetium Tc-99m disofenin

Administer dose of 1 to 5 mCi intravenously
Dosing modification
Renal Impairment
No dose modification required
Hepatic Impairment
for serum bilirubin >5 mg/dL: dose of 3 to 8 mCi

mangafodipir

Indicated for Diagnostic Magnetic Resonance Imaging:

For imaging of the liver, it should be given as an intravenous infusion at a rate of 2 to 3 ml/min and imaging of the pancreas at a rate of 4 to 6 ml/min.
The recommended dose is 0.5 ml/kg bodyweight (5 μmol/kg bodyweight).
This corresponds to a dose of 35 ml for a 70 kg person.
Above 100 kg body weight, 50 ml is usually sufficient to provide a diagnostically adequate contrast effect.